These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36193676)

  • 1. Clinicopathological analysis of a superior sulcus tumor treated by salvage surgery after concurrent definitive chemoradiotherapy followed by durvalumab: A case report.
    Funaki S; Ose N; Kimura T; Kanou T; Fukui E; Shintani Y
    Thorac Cancer; 2022 Nov; 13(22):3229-3232. PubMed ID: 36193676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage Surgery Post Definitive Chemoradiotherapy and Durvalumab for Lung Cancer.
    Minegishi K; Tsubochi H; Ohno K; Komori K; Ozeki M; Endo S
    Ann Thorac Surg; 2021 Jul; 112(1):e53-e55. PubMed ID: 33373589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study protocol for JCOG1807C (DEEP OCEAN): a interventional prospective trial to evaluate the efficacy and safety of durvalumab before and after operation or durvalumab as maintenance therapy after chemoradiotherapy against superior sulcus non-small cell lung cancer.
    Aokage K; Tsuboi M; Zenke Y; Horinouchi H; Nakamura N; Ishikura S; Nishikawa H; Kumagai S; Koyama S; Kanato K; Kataoka T; Wakabayashi M; Fukutani M; Fukuda H; Ohe Y; Watanabe SI;
    Jpn J Clin Oncol; 2022 Apr; 52(4):383-387. PubMed ID: 34999817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab.
    Fukui T; Hosotani S; Soda I; Ozawa T; Kusuhara S; Kakegawa MI; Kasajima M; Hiyoshi Y; Igawa S; Yokoba M; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Ishiyama H; Naoki K
    Thorac Cancer; 2020 Apr; 11(4):1005-1014. PubMed ID: 32057187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of salvage resection following locoregional failure after chemoradiotherapy and consolidation durvalumab for unresectable stage III non-small cell lung cancer.
    Dickhoff C; Unal S; Heineman DJ; Winkelman JA; Braun J; Bahce I; van Dorp M; Senan S; Dahele M
    Lung Cancer; 2023 Aug; 182():107294. PubMed ID: 37442060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined treatment modalities in Pancoast tumor: results of a monocentric retrospective study.
    Jeannin G; Merle P; Janicot H; Thibonnier L; Kwiatkowski F; Naame A; Chadeyras JB; Galvaing G; Belliere A; Filaire M; Verrelle P
    Chin Clin Oncol; 2015 Dec; 4(4):39. PubMed ID: 26730751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
    Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
    Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer.
    Mayahara H; Uehara K; Harada A; Kitatani K; Yabuuchi T; Miyazaki S; Ishihara T; Kawaguchi H; Kubota H; Okada H; Ninomaru T; Shindo C; Hata A
    Radiat Oncol; 2022 Jan; 17(1):7. PubMed ID: 35033139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage Surgery Compared to Surgery After Induction Chemoradiation Therapy for Advanced Lung Cancer.
    Kobayashi AK; Nakagawa K; Nakayama Y; Ohe Y; Yotsukura M; Uchida S; Asakura K; Yoshida Y; Watanabe SI
    Ann Thorac Surg; 2022 Dec; 114(6):2087-2092. PubMed ID: 34843695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibition With Chemoradiotherapy in Stage III Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis of Safety Results.
    Balasubramanian A; Onggo J; Gunjur A; John T; Parakh S
    Clin Lung Cancer; 2021 Mar; 22(2):74-82. PubMed ID: 33414053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population-based survival rates after curative surgical and non-surgical treatment of stage III NSCLC since 2017.
    Damhuis RAM; Dickhoff C; Bahce I; Senan S
    Lung Cancer; 2024 Apr; 190():107532. PubMed ID: 38461767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trimodality vs Chemoradiation and Salvage Resection in cN2 Stage IIIA Non-Small Cell Lung Cancer.
    Ye JC; Ding L; Atay SM; Nieva JJ; McFadden PM; Chang E; Kim AW
    Semin Thorac Cardiovasc Surg; 2020; 32(1):153-159. PubMed ID: 31220530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage Surgery After Definitive Chemoradiotherapy for Non-small Cell Lung Cancer.
    Casiraghi M; Maisonneuve P; Piperno G; Bellini R; Brambilla D; Petrella F; Marinis F; Spaggiari L
    Semin Thorac Cardiovasc Surg; 2017 Summer; 29(2):233-241. PubMed ID: 28823336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer.
    Chu CH; Chiu TH; Wang CC; Chang WC; Huang AC; Liu CY; Wang CL; Ko HW; Chung FT; Hsu PC; Guo YK; Kuo CS; Yang CT
    Thorac Cancer; 2020 Jun; 11(6):1541-1549. PubMed ID: 32281272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of combined modality treatment in patients with non-small-cell lung cancer of the superior sulcus and the rationale for surgical resection.
    Kappers I; van Sandick JW; Burgers JA; Belderbos JS; Wouters MW; van Zandwijk N; Klomp HM
    Eur J Cardiothorac Surg; 2009 Oct; 36(4):741-6. PubMed ID: 19699647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.
    Rajappa S; Sharma S; Prasad K
    Adv Ther; 2019 Mar; 36(3):563-578. PubMed ID: 30693419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage surgery after definitive chemo-radiotherapy for patients with Non-Small Cell Lung Cancer.
    Romero-Vielva L; Viteri S; Moya-Horno I; Toscas JI; Maestre-Alcácer JA; Ramón Y Cajal S; Rosell R
    Lung Cancer; 2019 Jul; 133():117-122. PubMed ID: 31200817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Survival after Salvage Surgery for Local Failure after Definitive Chemoradiation Therapy for Locally Advanced Non-small Cell Lung Cancer.
    Schreiner W; Dudek W; Lettmaier S; Fietkau R; Sirbu H
    Thorac Cardiovasc Surg; 2018 Mar; 66(2):135-141. PubMed ID: 28992654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage Lung Resections After Definitive Chemoradiotherapy: A Safe and Effective Oncologic Option.
    Bograd AJ; Mann C; Gorden JA; Gilbert CR; Farivar AS; Aye RW; Louie BE; Vallières E
    Ann Thorac Surg; 2020 Oct; 110(4):1123-1130. PubMed ID: 32473131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [When Should We Perform Surgery for N2 Lung Cancer?;Induction Chemoradiotherapy or Surgery for Local Recurrence or Residual Tumor after Definitive Chemoradiotherapy].
    Ito H; Nakayama H
    Kyobu Geka; 2018 Apr; 71(4):290-299. PubMed ID: 29755103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.